Clinical Study of DA-001 as a Treatment for Telogen Effluvium

Launched by APPLIED BIOLOGY, INC. · Oct 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called DA-001 for women who have been diagnosed with telogen effluvium, a condition that causes hair loss. The main goal of the study is to see how safe and effective DA-001 is in helping to treat this condition. The trial is not yet recruiting participants, but once it begins, it will look for women aged 18 and older who are otherwise healthy and willing to follow the treatment guidelines.

To participate, women should not be pregnant, breastfeeding, or planning to become pregnant during the study. They also need to have no significant medical issues that could affect the trial's results, and they shouldn't have used certain medications or had specific treatments in the month before starting the study. If eligible, participants can expect to apply the treatment as directed and attend scheduled visits to monitor their progress. This study aims to provide valuable insights into a potential new option for managing telogen effluvium.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 or older
• • Diagnosed with telogen effluvium
• • Willing and able to apply the treatment as directed, comply with study
• • Otherwise healthy
• • Able to give informed consent
• Exclusion Criteria:
• • A medical history that may interfere with study objectives
• • Women who are pregnant, lactating, or planning to become pregnant during the study period
• • Subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc)
• • Subjects who have known allergies to any excipient in DA-001
• • Subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation
• • Subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation
• • Subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation
• • Subject is unable to provide consent or make the allotted clinical visits